Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHXM-002
- Development stage
- Preclinical
- Lead developer
- ChomiX Biotech
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
CHXM-002 is an experimental radionuclide drug conjugate (RDC) currently in the hit identification stage of preclinical development by ChomiX. The drug is designed using ChomiX's proprietary chemoproteomics platform, which identifies novel ligands for previously undruggable targets. CHXM-002 consists of a small molecule targeting a specific membrane protein expressed on tumor cells, conjugated to a radionuclide payload. This approach is intended to deliver localized, lethal radiation directly to cancerous tissues while sparing healthy cells. It is being developed as a targeted therapy for various solid tumors.
Beyond the preview
Go deeper on CHXM-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHXM-002.